Literature DB >> 6318629

NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

A S Fauci, A M Macher, D L Longo, H C Lane, A H Rook, H Masur, E P Gelmann.   

Abstract

The acquired immunodeficiency syndrome is a new disease whose cause is unknown but is almost surely due to a transmissible agent, most likely a virus. The disease is clearly spread by sexual contact, particularly homosexual activity. Blood-borne transmission constitutes the other major recognized form of spread of the disease, although it is highly likely that the disease is not readily spread through casual, nonsexual, non-blood-borne routes. Although the disease is still highly concentrated in the United States, it is now seen in several countries throughout the world. The common denominator of the disease is a profound suppression of cell-mediated immunity, specifically a quantitative and qualitative defect in the T4 inducer or helper subset of T lymphocytes. Hyperactivity of B lymphocytes is also characteristic. The clinical manifestations are those of severe and life-threatening opportunistic infections and unusual neoplasms, particularly Kaposi's sarcoma. The mortality may well approach 100%, making this one of the most extraordinary transmissible diseases in history.

Entities:  

Mesh:

Year:  1984        PMID: 6318629     DOI: 10.7326/0003-4819-100-1-92

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  186 in total

1.  Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.

Authors:  D Schenten; L Marcon; G B Karlsson; C Parolin; T Kodama; N Gerard; J Sodroski
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Susceptibility to a mouse acquired immunodeficiency syndrome is influenced by the H-2.

Authors:  D Hamelin-Bourassa; E Skamene; F Gervais
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

3.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry.

Authors:  M Cayabyab; S Hinuma; M Farzan; H Choe; S Fukusumi; C Kitada; N Nishizawa; M Hosoya; O Nishimura; T Messele; G Pollakis; J Goudsmit; M Fujino; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Characterization of the cDNA of a broadly reactive neutralizing human anti-gp120 monoclonal antibody.

Authors:  W A Marasco; J Bagley; C Zani; M Posner; L Cavacini; W A Haseltine; J Sodroski
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

6.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  IgA1 is the major immunoglobulin component of immune complexes in the acquired immune deficiency syndrome.

Authors:  S Jackson; L M Dawson; D P Kotler
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

8.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 9.  The molecular structure of human antibodies specific for the human immunodeficiency virus.

Authors:  J S Andris; J D Capra
Journal:  J Clin Immunol       Date:  1995-01       Impact factor: 8.317

10.  HIV infection presenting as renal polyarteritis nodosa.

Authors:  J C Angulo; J I Lopez; M E Garcia; J Peiro; N Flores
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.